Product image of Metformina + Sitagliptina Grindeks (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Metformina + Sitagliptina Grindeks

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Metformina + Sitagliptina Grindeks (Metformin Hydrochloride, Sitagliptin)

Metformin hydrochloride and sitagliptin, the active ingredients in Metformina + Sitagliptina Grindeks, constitute a biguanide and DPP‑4 inhibitor presented as a fixed‑dose oral tablet for oral use. The combination is indicated for the management of type 2 diabetes mellitus in adult patients when diet, exercise, and monotherapy are insufficient.

GNH India supplies Metformina + Sitagliptina Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable delivery across multiple continents through a robust logistics network.

Manufacturer / TM Owner

Grindeks

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metformina + Sitagliptina Grindeks is used in the management of type 2 diabetes mellitus, targeting hyperglycemia through complementary mechanisms.

  • Type 2 diabetes mellitus: improves overall glycemic control when diet, exercise, and monotherapy are insufficient.
  • Adjunct to metformin therapy: provides additional glucose‑lowering effect for patients inadequately controlled on metformin alone.
  • Combination therapy with other antidiabetics: enables dual action alongside sulfonylureas, insulin or GLP‑1 agonists to achieve target HbA1c.

How It Works

  • Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, while sitagliptin inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, increasing endogenous incretin levels (GLP‑1 and GIP). The elevated incretins promote glucose‑dependent insulin secretion and suppress glucagon release, together providing complementary glucose‑lowering effects in type 2 diabetes.

Side Effects

The combination may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

  • Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
  • Headache: mild to moderate intensity.
  • Mild hypoglycemia: especially when used with sulfonylureas or insulin.
  • Upper respiratory tract infection: transient symptoms.

Serious or Rare Side Effects

  • Lactic acidosis: a rare but potentially fatal metabolic complication.
  • Acute pancreatitis: severe abdominal pain with elevated enzymes.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Hepatic failure: signs of liver dysfunction.
  • Severe hypoglycemia: prolonged loss of consciousness or seizures.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

  • Renal function: assess eGFR and avoid use in severe renal impairment.
  • Hepatic disease: use with caution; monitor liver enzymes.
  • Risk of lactic acidosis: contraindicated in conditions predisposing to hypoxia.
  • Pregnancy and lactation: discuss potential risks with the prescriber.
  • Drug interactions: review concomitant medications for additive hypoglycemic risk.
  • Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Metformina + Sitagliptina may interact with several drug classes, requiring careful assessment.

Major Interactions (Avoid)

  • Severe renal impairment: contraindicates metformin component.
  • Strong CYP2C8 inhibitors (e.g., gemfibrozil): may increase metformin exposure.
  • Concurrent use of another DPP‑4 inhibitor: duplicate pharmacologic effect.

Moderate Interactions (Monitor Closely)

  • Sulfonylureas or insulin: heightened risk of hypoglycemia.
  • Loop diuretics: may affect renal clearance of metformin.
  • Iodinated contrast agents: temporary discontinuation of metformin recommended.
  • Alcohol excess: increases lactic acidosis risk.
  • Beta‑blockers: may mask hypoglycemia symptoms.

Frequently Asked Questions

Metformina + Sitagliptina is prescribed for the treatment of type 2 diabetes mellitus in adults. It combines two mechanisms—decreasing hepatic glucose output and enhancing incretin activity—to improve overall blood‑sugar control when diet, exercise, or single‑agent therapy are insufficient.

Metformin hydrochloride lowers blood glucose primarily by inhibiting hepatic gluconeogenesis and increasing peripheral insulin sensitivity. This reduces the amount of glucose released into the bloodstream and improves the uptake of glucose by muscle and fat tissues, contributing to better glycemic control.

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on individual patient factors such as renal function, current glycemic control, and concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety in pregnancy and lactation has not been fully established. The prescriber should evaluate the potential benefits against possible risks before initiating therapy in pregnant or nursing women, and alternative treatments may be considered when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with metformin monotherapy, the addition of sitagliptin offers a complementary DPP‑4 inhibition pathway, often resulting in greater HbA1c reduction. Unlike sulfonylureas, it carries a lower intrinsic risk of hypoglycemia, and unlike insulin, it is administered orally without injection.

Store the tablets at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Do not store in bathrooms or near heat sources, and keep out of reach of children.

The medication is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a full glass of water and not crushed or chewed unless specifically instructed.

The most serious risks include lactic acidosis, a rare but potentially fatal condition linked to metformin, and acute pancreatitis related to sitagliptin. Patients should be aware of symptoms such as severe abdominal pain, unexplained fatigue, rapid breathing, or muscle pain and seek immediate medical attention if they occur.

Patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, or a history of lactic acidosis should avoid this medication. It is also contraindicated in individuals with certain hepatic conditions or in those taking other DPP‑4 inhibitors.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT